BRIDGEWAY CAPITAL MANAGEMENT, LLC

Position in ACRS — Aclaris Therapeutics, Inc.

CIK 1107261 HOUSTON, TX

Position in ACRS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$1,237,571

+$244,214 QoQ

Shares Held

330,019

0.0% QoQ

Ownership

0.236%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2020

13 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

BRIDGEWAY CAPITAL MANAGEMENT, LLC holds $59,315,164 across 112 Biotechnology names. ACRS ranks #9 (2.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	GLUE	Monte Rosa Therapeutics, Inc.	528,698	$8,697,082
2	PBYI	Puma Biotechnology, Inc.	775,341	$4,954,428
3	EXEL	Exelixis, Inc.	66,100	$2,835,029
4	KROS	Keros Therapeutics, Inc.	195,017	$2,152,987
5	SGMT	Sagimet Biosciences Inc.	299,641	$1,565,624
6	BDTX	Black Diamond Therapeutics, Inc.	723,477	$1,541,006
7	PTCT	Ptc Therapeutics, Inc.	22,000	$1,498,860
8	KYTX	Kyverna Therapeutics, Inc.	149,900	$1,293,637

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,237,571	330,019	0.0%	Shares	Sole	2026-05-15
2025-12-31	$993,357	330,019	-16.1%	Shares	Sole	2026-02-17
2025-09-30	$747,306	393,319	-11.3%	Shares	Sole	2025-11-14
2025-06-30	$629,512	443,319	+53.5%	Shares	Sole	2025-08-14
2025-03-31	$441,740	288,719	+2.7%	Shares	Sole	2025-05-15
2024-12-31	$697,175	281,119	+41.2%	Shares	Sole	2025-02-14
2024-09-30	$228,986	199,119	+32.1%	Shares	Sole	2024-11-14
2024-06-30	$165,770	150,700	+11.6%	Shares	Sole	2024-08-14
2021-06-30	$2,370,600	135,000	-37.0%	Shares	Sole	2021-08-16
2021-03-31	$5,400,360	214,300	-10.5%	Shares	Sole	2021-05-17
2020-12-31	$1,548,918	239,400	-12.8%	Shares	Sole	2021-02-16
2020-09-30	$705,208	274,400	0.0%	Shares	Sole	2020-11-16
2020-06-30	$444,528	274,400	—	Shares	Sole	2020-08-31
No filing history on record for this holder in this stock.